Treating genes and patients

John Wilson^{1

2}

Affiliations

¹ Cystic Fibrosis Service, Alfred Health, Melbourne, Australia. john.wilson@monash.edu.
² Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia. john.wilson@monash.edu.

Comment

John Wilson. Gene Ther. 2020 Apr.

. 2020 Apr;27(3-4):109-110.

doi: 10.1038/s41434-019-0111-6. Epub 2019 Nov 27.

John Wilson^{1

2}

¹ Cystic Fibrosis Service, Alfred Health, Melbourne, Australia. john.wilson@monash.edu.
² Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia. john.wilson@monash.edu.

No abstract available

Comment on

Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis.
Schneider-Futschik EK. Schneider-Futschik EK. Gene Ther. 2019 Sep;26(9):354-362. doi: 10.1038/s41434-019-0092-5. Epub 2019 Jul 12. Gene Ther. 2019. PMID: 31300729 Review.

1. Knowlton RG, Cohen-Haguenauer O, Van Cong N, Frezal J, Brown VA, Barker D, et al. A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. Nature. 1985;318:380–2. - DOI
1. De Boeck K, Amaral MD. Classification of CFTR mutation classes—authors’ reply. Lancet Respir Med. 2016;4:e39. - DOI
1. Scott O, Kim VH, Reid B, Pham-Huy A, Atkinson AR, Aiuti A, et al. Long-term outcome of adenosine deaminase-deficient patients-a single-center experience. J Clin Immunol. 2017;37:582–91. - DOI
1. Thrasher AJ, Williams DA. Evolving gene therapy in primary immunodeficiency. Mol Ther. 2017;25:1132–41. - DOI
1. Conese M, Rejman J. Stem cells and cystic fibrosis. J Cyst Fibros. 2006;5:141–3. - DOI